HealthEquity reported strong fiscal 2026 results with HSAs growing 7% to 10.6 million accounts and total accounts reaching 17.8 million. HSA assets increased 14% to $36.5 billion, with HSA investments surging 26% to $18.5 billion. The company achieved record fourth-quarter new HSA sales, growing 17% year-over-year, adding over one million new HSA accounts from sales during the fiscal year. HealthEquity reaffirmed guidance for fiscal 2026 and 2027.
HealthEquity, Inc (HQY)
Common Stock · Currency in USD · XNAS
HealthEquity Inc provides solutions that allow consumers to make healthcare saving and spending decisions. It provides payment processing services, personalized benefit information, the ability to earn wellness incentives, and investment advice to grow their tax-advantaged healthcare savings. It manages consumers' tax-advantaged health savings accounts (HSAs) and other consumer-directed benefits (CDBs) offered by employers, including flexible spending accounts and health reimbursement arrangements (FSAs and HRAs), and administers Consolidated Omnibus Budget Reconciliation Act (COBRA), commuter and other benefits. It also provides investment advisory services to customers whose account balances exceed a certain threshold. HealthEquity generates its revenue in the United States.
Company Info
SIC7389
Composite FIGIBBG000TYXCT9
CIK0001428336
IPOJul 31, 2014
Sectorservices-business services, nec
Highlights
Market Cap$7.15B
EPS$2.40
P/E Ratio34.59
Revenue$1.30B
Gross Profit$912.25M
Net Income$206.77M
Employees2,814
WSO84,478,406
Phone801-727-1000
Websitehttps://www.healthequity.com
Related Tickers
Analysis
Share Price Chart
Performance Chart
The chart shows the growth of an initial investment of $10,000 in HealthEquity, Inc, comparing it to the performance of the S&P 500 index.
All prices have been adjusted for splits and dividends.
Returns By Period
HealthEquity, Inc (HQY) has returned -7.69% so far this year and 13.73% over the past 12 months. Looking at the last ten years, HQY has achieved an annualized return of 12.95%, outperforming the Benchmark (SPY), which averaged 12.23% per year.
HQY
1M4.34%
6M-4.72%
YTD-7.69%
1Y13.73%
5Y4.03%
10Y12.95%
Benchmark (SPY)
1M-3.85%
6M-2.35%
YTD-4.36%
1Y34.06%
5Y9.80%
10Y12.23%
Monthly Returns
The table below presents the monthly returns of HealthEquity, Inc (HQY) with color gradation from worst to best to easily spot seasonal factors.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | -6.60% | -10.31% | 10.86% | 0.77% | ||||||||
| 2025 | 15.18% | 1.39% | -19.67% | -2.35% | 16.49% | 4.25% | -6.96% | -6.01% | 6.47% | 0.85% | 10.81% | -12.68% |
| 2024 | 13.40% | 9.90% | -1.16% | -3.09% | 3.41% | 5.46% | -9.27% | 1.40% | 3.14% | 4.14% | 17.86% | -5.77% |
| 2023 | -0.98% | 7.33% | -9.55% | -8.69% | 2.35% | 15.41% | 7.23% | -0.57% | 8.19% | -1.66% | -5.90% | -0.20% |
| 2022 | 19.66% | 0.39% | 26.70% | -7.19% | 0.58% | -2.26% | -4.50% | 14.66% | 2.47% | 14.79% | -18.49% | -2.64% |
| 2021 | 19.85% | -0.54% | -19.41% | 11.13% | 8.84% | -2.61% | -7.97% | -13.81% | 0.20% | 0.96% | -17.68% | -20.36% |
| 2020 | -11.91% | 6.86% | -28.85% | 16.82% | 13.56% | -4.83% | -11.89% | 10.39% | -10.63% | -0.06% | 36.27% | -4.35% |
| 2019 | 6.93% | 28.83% | -9.12% | -9.35% | -4.42% | 0.21% | 23.07% | -27.86% | -3.68% | -1.59% | 9.28% | 17.76% |
| 2018 | 7.73% | 13.59% | 5.20% | 8.13% | 13.68% | 1.10% | 1.44% | 24.98% | -0.61% | -3.67% | -4.99% | -34.82% |
| 2017 | 12.92% | -6.38% | -3.87% | 7.43% | 0.48% | 9.93% | -8.64% | -7.28% | 17.68% | -1.14% | 2.55% | -10.25% |
| 2016 | 2.95% | 2.50% | 18.18% | -2.57% | 10.56% | 16.68% | -11.83% | 33.48% | -9.07% |
Performance Indicators
The charts below present risk-adjusted performance metrics for HealthEquity, Inc (HQY) and compare them to a Benchmark (SPY). These indicators evaluate an investment's returns against its associated risks.
Sharpe ratio
Sortino ratio
Omega ratio
Calmar ratio
Martin ratio
sharpe ratio
The Sharpe ratio helps investors understand how much return they're getting for the level of risk taken. A higher Sharpe ratio indicates better risk-adjusted performance, meaning more reward for each unit of risk.
These values reflect how efficiently the investment has delivered returns relative to its volatility over different time periods. All figures are annualized and based on daily total returns.
The chart below shows the rolling Sharpe ratio of HQY compared to the benchmark. This view highlights how the investment's risk-adjusted performance has changed over time.
Volatility Chart
The current HealthEquity, Inc volatility is 1.44%, representing the standart deviation of percentage change in the investments's value, either up or down over the past month. The chart below shows the rolling one-month volatility.
Drawdowns Chart
The Drawdowns chart displays portfolio losses from any high point along the way. It shows the maximum percentage drop from a peak to a trough over a specified period, indicating the risk of significant losses.
Although chart shows positive values, it represents the percentage drop from the peak, so a value of 10% means the portfolio has dropped 10% from its highest point.
Income Statement
The income statement provides a summary of a company's revenues, expenses, and profits over a specific period. It shows how much money the company earned (revenues) and how much it spent (expenses), leading to the net income or profit. This statement is crucial for understanding a company's financial performance and profitability.
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Liabilities And Equity (USD) | 3.45B | 3.16B | 3.09B | 3.11B | 2.71B | 2.56B | 510.02M | 369.16M | 279.14M | 219.80M | 158.77M |
| Temporary Equity Attributable To Parent (USD) | - | - | - | - | - | - | - | - | - | - | - |
| Temporary Equity (USD) | - | - | - | - | - | - | - | - | - | - | - |
| Equity Attributable To Parent (USD) | 2.11B | 2.04B | 1.90B | 1.85B | 1.38B | 1.03B | 477.08M | 346.27M | 261.94M | 203.46M | 144.10M |
| Equity Attributable To Noncontrolling Interest (USD) | - | - | - | - | - | - | - | - | - | - | - |
| Equity (USD) | 2.11B | 2.04B | 1.90B | 1.85B | 1.38B | 1.03B | 477.08M | 346.27M | 261.94M | 203.46M | 144.10M |
| Other Non-current Liabilities (USD) | 121.02M | 136.71M | 136.86M | 170.51M | 123.85M | 162.05M | - | - | - | - | - |
| Long-term Debt (USD) | 1.06B | 874.97M | 925.34M | 930.83M | 1.00B | 1.22B | - | - | - | - | - |
| Noncurrent Liabilities (USD) | 1.18B | 1.01B | 1.06B | 1.10B | 1.13B | 1.38B | 3.88M | 2.40M | 1.49M | 4.23M | 5.84M |
| Other Current Liabilities (USD) | 72.63M | 55.44M | 71.33M | 78.51M | 152.42M | 97.84M | 8.55M | 5.52M | 3.76M | 1.90M | 2.23M |
| Wages (USD) | 69.33M | 49.61M | 45.84M | 47.14M | 50.67M | 50.12M | 16.98M | 12.55M | 8.72M | 7.78M | 5.30M |
| Accounts Payable (USD) | 14.36M | 12.04M | 13.90M | 27.54M | 1.61M | 3.98M | 3.52M | 2.42M | 3.22M | 2.43M | 1.30M |
| Current Liabilities (USD) | 156.32M | 117.09M | 131.06M | 153.19M | 204.70M | 151.94M | 29.05M | 20.49M | 15.70M | 12.11M | 8.83M |
| Liabilities (USD) | 1.33B | 1.13B | 1.19B | 1.25B | 1.33B | 1.53B | 32.94M | 22.89M | 17.20M | 16.34M | 14.67M |
| Other Non-current Assets (USD) | 1.76B | 1.76B | 1.76B | 1.76B | 1.45B | 1.45B | 27.45M | 12.29M | 8.13M | 6.40M | 4.93M |
| Intangible Assets (USD) | 1.20B | 835.95M | 936.36M | 973.14M | 767.00M | 783.28M | 79.67M | 83.64M | 65.02M | 66.84M | 26.54M |
| Fixed Assets (USD) | 3.24M | 6.01M | 12.86M | 23.37M | 29.11M | 33.49M | 8.22M | 7.84M | 5.17M | 3.51M | 2.58M |
| Noncurrent Assets (USD) | 2.97B | 2.61B | 2.71B | 2.76B | 2.25B | 2.27B | 115.34M | 103.76M | 78.32M | 76.75M | 34.05M |
| Other Current Assets (USD) | - | - | - | - | - | - | 33.20M | 24.56M | 19.60M | 18.50M | 121.82M |
| Prepaid Expenses (USD) | - | - | - | - | - | - | - | - | - | - | 2.27M |
| Inventory (USD) | - | - | - | - | - | - | - | 215.00K | 592.00K | 620.00K | 625.00K |
| Cash (USD) | - | - | - | - | - | - | 361.48M | 240.63M | 180.62M | 123.93M | - |
| Current Assets (USD) | 477.75M | 557.44M | 382.89M | 351.34M | 460.18M | 297.30M | 394.68M | 265.40M | 200.82M | 143.05M | 124.72M |
| Assets (USD) | 3.45B | 3.16B | 3.09B | 3.11B | 2.71B | 2.56B | 510.02M | 369.16M | 279.14M | 219.80M | 158.77M |
News and Insights
HealthEquity reported strong Q2 fiscal 2026 financial results with 9% revenue growth and 67% net income increase, while experiencing slower organic HSA account sales and raising full-year guidance.
HealthEquity introduced HSAnswers, an AI-powered educational tool that provides personalized responses to complex healthcare benefits questions, winning multiple industry awards for its innovative approach to simplifying benefits information.
HealthEquity Announces First Quarter Earnings Release Date Presentations at Investor Conferencespositive
HealthEquity, the largest HSA custodian, announced plans to release its Q1 FY2026 financial results and host a conference call on June 3, 2025. The company also announced upcoming investor conference presentations.
HealthEquity, Inc. reported weaker-than-expected Q4 earnings and provided weak guidance for FY2026, citing increased cyber threats and fraud attacks, causing its stock price to drop significantly.
HealthEquity, Inc. (HQY) shares fell 17% on March 19, 2025, after the company missed profit estimates and gave weak guidance due to rising criminal activity targeting the firm.
HealthEquity, Inc. (NASDAQ: HQY) shares fell 17% on March 19, 2025, after the company missed profit estimates and gave weak guidance due to rising criminal activity targeting the firm.
Pomerantz LLP is investigating claims on behalf of investors of OSI Systems, Inc. (OSIS) following a short report by Culper Research that alleges the company's reported growth in Mexico revenues is 'largely an illusion' and accuses it of 'downplaying' U.S. Department of Justice investigations.
HealthEquity, Inc. reported weaker-than-expected Q4 earnings and provided weak guidance for FY2026, citing increased cyber threats and fraud attacks, causing its stock price to drop significantly.
A securities class action lawsuit has been filed against Actinium Pharmaceuticals, Inc. (ATNM) for allegedly making false and/or misleading statements during the class period. Investors are encouraged to secure counsel before the May 26, 2025 lead plaintiff deadline.